$11.57
3.12% yesterday
Nasdaq, Oct 17, 10:00 pm CET
ISIN
US15687V1098
Symbol
CERT

Certara Stock price

$11.57
+0.74 6.83% 1M
-5.38 31.74% 6M
-6.02 34.22% YTD
-2.52 17.89% 1Y
-25.03 68.39% 3Y
-26.51 69.62% 5Y
-26.51 69.62% 10Y
Nasdaq, Closing price Thu, Oct 17 2024
+0.35 3.12%
ISIN
US15687V1098
Symbol
CERT

Key metrics

Market capitalization $1.86b
Enterprise Value $1.95b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 29.26
EV/Sales (TTM) EV/Sales 5.36
P/S ratio (TTM) P/S ratio 5.12
P/B ratio (TTM) P/B ratio 1.78
Revenue growth (TTM) Revenue growth 3.26%
Revenue (TTM) Revenue $363.55m
EBIT (operating result TTM) EBIT $-11.01m
Free Cash Flow (TTM) Free Cash Flow $66.62m
Cash position $224.60m
EPS (TTM) EPS $-0.49
P/E forward negative
P/S forward 4.82
EV/Sales forward 5.05
Short interest 3.24%
Show more

Is Certara a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.

Certara Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Certara forecast:

4x Buy
36%
7x Hold
64%

Analyst Opinions

11 Analysts have issued a Certara forecast:

Buy
36%
Hold
64%

Financial data from Certara

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
364 364
3% 3%
100%
- Direct Costs 199 199
11% 11%
55%
165 165
5% 5%
45%
- Selling and Administrative Expenses 76 76
79% 79%
21%
- Research and Development Expense 38 38
26% 26%
10%
51 51
49% 49%
14%
- Depreciation and Amortization 62 62
16% 16%
17%
EBIT (Operating Income) EBIT -11 -11
123% 123%
-3%
Net Profit -79 -79
510% 510%
-22%

In millions USD.

Don't miss a Thing! We will send you all news about Certara directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Certara Stock News

Neutral
GlobeNewsWire
one day ago
RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024.
Neutral
GlobeNewsWire
8 days ago
RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.
Neutral
GlobeNewsWire
15 days ago
Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry.
More Certara News

Company Profile

Certara, Inc. engages in the provision of software and technology enables services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017 and is headquartered in Princeton, NJ.

Head office United States
CEO William Feehery
Employees 1,391
Founded 2008
Website www.certara.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today